Stefan Weiskopf - Zoetis President

ZTS -- USA Stock  

USD 119.64  1.38  1.14%

Mr. Stefan Weiskopf serves as Executive Vice President Area President of the Asia Pacific of Zoetis Inc. Mr. Weiskopf was Area President of that region for Pfizer Animal Health from 2007 to 2012. Mr. Weiskopf joined Pfizer in 1988 and held various positions including Division Director Animal Health for Germany Austria and Switzerland.
Age: 54  President Since 2013      

Stefan Weiskopf Latest Insider Activity

Management Efficiency

The company has Return on Asset of 12.56 % which means that on every $100 spent on asset it made $12.56 of profit. This is considered to be average in the sector. In the same way, it shows return on shareholders equity (ROE) of 62.6 % implying that it generated $62.6 on every 100 dollars invested.
The company has 6.65B in debt with debt to equity (D/E) ratio of 275.9 . This implies that the company may be unable to create cash to meet all of its financial commitments. Zoetis has Current Ratio of 4.09 demonstrating that it is liquid and is capable to disburse its financial commitments when the payables are due.

Similar Executives

Showing few of many executives


Michael AbermanRegeneron Pharmaceuticals
Paul WeningerPerrigo Company plc
Marc CouckePerrigo Company plc
Sripada ChandrasekharDr Reddys Laboratories Ltd
Thomas FarringtonPerrigo Company plc
Jeffrey ChodakewitzVertex Pharmaceuticals Incorpor
K RaoDr Reddys Laboratories Ltd
Kimberly WhiteVertex Pharmaceuticals Incorpor
John GrayVertex Pharmaceuticals Incorpor
Amit BiswasDr Reddys Laboratories Ltd
Jay MarkowitzRegeneron Pharmaceuticals
Ganadhish KamatDr Reddys Laboratories Ltd
Ronald JanishPerrigo Company plc
Charles MilsteinVertex Pharmaceuticals Incorpor
Jatin ShahPerrigo Company plc
Charles WagnerVertex Pharmaceuticals Incorpor
Christopher FenimoreRegeneron Pharmaceuticals
Amit SachdevVertex Pharmaceuticals Incorpor
Jeffrey NeedhamPerrigo Company plc
Svend AndersenPerrigo Company plc
Saumen ChakrabortyDr Reddys Laboratories Ltd

Entity Summary

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. The company was founded in 1952 and is headquartered in Parsippany, New Jersey. Zoetis operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 10000 people.Zoetis (ZTS) is traded on BATS Exchange in USA and employs 10,000 people.

Zoetis Leadership Team

Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply
Kristin Peck, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy
William Steere, Independent Director
Roxanne Lagano, Executive Vice President, Chief Human Resources Officer and Communications
Linda Rhodes, Independent Director
Frank DAmelio, Independent Director
Robert Scully, Independent Director
Clinton Lewis, Executive Vice President and Group President, International Operations, Commercial Development, Global Genetics, Aquatic Health and Human Medical Diagnostics
Stefan Weiskopf, Executive Vice President and Area President of the Asia Pacific, Australia and New Zealand
Sanjay Khosla, Independent Director
Paul Herendeen, CFO and Executive VP
Catherine Knupp, Executive Vice President, President - Research and Development
Michael McCallister, Non-Executive Independent Chairman of the Board
Paul Bisaro, Independent Director
Alejandro Bernal, Executive Vice President and Area President of the Europe, Africa and Middle East region
Willie Reed, Independent Director
Joyce Lee, Executive Vice President and Area President of the Canada and Latin America region
Glenn David, Chief Financial Officer, Executive Vice President
Sandra Beaty, Executive Vice President - Corporate Affairs
William Doyle, Director
Andrew Fenton, Executive Vice President and Chief Digital and Technology Officer
Gregory Norden, Independent Director
Louise Parent, Independent Director
Heidi Chen, Executive Vice President General Counsel, Corporate Secretary
Juan Alaix, Chief Executive Officer, Director

Stock Performance Indicators

Did you try this?

Run Portfolio Anywhere Now


Portfolio Anywhere

Track or share privately all of your investments from the convenience of any device
All  Next Launch Module

Also Currentnly Active

Purchased over 20 shares of
1 hour ago
Traded for 135.34
Purchased a lot of shares of
1 hour ago
Traded for 155.87
Purchased over 70 shares of
1 hour ago
Traded for 35.56
See also Your Current Watchlist. Please also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.